The University of Chicago Header Logo

Connection

Gregory Karczmar to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Gregory Karczmar has written about Prostatic Neoplasms.
Gregory Karczmar
Connection Strength
7.545
Prostatic Neoplasms
  1. Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI. Magn Reson Med. 2024 Jul; 92(1):319-331.
    View in: PubMed
    Score: 0.413
  2. Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer. Med Phys. 2024 Mar; 51(3):2057-2065.
    View in: PubMed
    Score: 0.401
  3. Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer. Phys Eng Sci Med. 2023 Sep; 46(3):1215-1226.
    View in: PubMed
    Score: 0.397
  4. Directional and inter-acquisition variability in diffusion-weighted imaging and editing for restricted diffusion. Magn Reson Med. 2022 11; 88(5):2298-2310.
    View in: PubMed
    Score: 0.372
  5. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.
    View in: PubMed
    Score: 0.354
  6. High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magn Reson Med. 2021 09; 86(3):1505-1513.
    View in: PubMed
    Score: 0.342
  7. Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data. Phys Med Biol. 2021 01 22; 66(2):025002.
    View in: PubMed
    Score: 0.335
  8. A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Phys Med Biol. 2019 08 07; 64(15):155012.
    View in: PubMed
    Score: 0.303
  9. Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
    View in: PubMed
    Score: 0.299
  10. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.
    View in: PubMed
    Score: 0.285
  11. Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
    View in: PubMed
    Score: 0.273
  12. Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
    View in: PubMed
    Score: 0.233
  13. Hybrid multidimensional T(2) and diffusion-weighted MRI for prostate cancer detection. J Magn Reson Imaging. 2014 Apr; 39(4):781-8.
    View in: PubMed
    Score: 0.200
  14. Hyperthermically induced changes in high spectral and spatial resolution MR images of tumor tissue--a pilot study. Phys Med Biol. 2012 May 07; 57(9):2653-66.
    View in: PubMed
    Score: 0.182
  15. Can DCEMRI assess the effect of green tea on the angiogenic properties of rodent prostate tumors? Phys Med. 2010 Apr; 26(2):111-6.
    View in: PubMed
    Score: 0.151
  16. Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR images. Magn Reson Med. 2009 Feb; 61(2):291-8.
    View in: PubMed
    Score: 0.146
  17. Comparison of high-resolution echo-planar spectroscopic imaging with conventional MR imaging of prostate tumors in mice. NMR Biomed. 2005 Aug; 18(5):285-92.
    View in: PubMed
    Score: 0.115
  18. Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer. Cancer Imaging. 2024 Jul 08; 24(1):89.
    View in: PubMed
    Score: 0.106
  19. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med. 2004 Mar; 51(3):487-94.
    View in: PubMed
    Score: 0.104
  20. Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
    View in: PubMed
    Score: 0.099
  21. An Interactive App with Multi-parametric MRI - Whole-Mount Histology Correlation for Enhanced Prostate MRI Training of Radiology Residents. Acad Radiol. 2023 09; 30 Suppl 1:S21-S29.
    View in: PubMed
    Score: 0.098
  22. Comparing Radiologist Performance in Diagnosing Clinically Significant Prostate Cancer with Multiparametric versus Hybrid Multidimensional MRI. Radiology. 2022 11; 305(2):399-407.
    View in: PubMed
    Score: 0.093
  23. Physically implausible signals as a quantitative quality assessment metric in prostate diffusion-weighted MR imaging. Abdom Radiol (NY). 2022 07; 47(7):2500-2508.
    View in: PubMed
    Score: 0.092
  24. Functional and anatomic imaging of tumor vasculature: high-resolution MR spectroscopic imaging combined with a superparamagnetic contrast agent. Acad Radiol. 2002 May; 9 Suppl 1:S115-8.
    View in: PubMed
    Score: 0.091
  25. Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures. Abdom Radiol (NY). 2022 02; 47(2):801-813.
    View in: PubMed
    Score: 0.089
  26. Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer? Acad Radiol. 2022 07; 29(7):977-985.
    View in: PubMed
    Score: 0.088
  27. Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Acad Radiol. 2022 06; 29(6):796-803.
    View in: PubMed
    Score: 0.088
  28. Differentiation of nonmetastatic and metastatic rodent prostate tumors with high spectral and spatial resolution MRI. Magn Reson Med. 2001 Jun; 45(6):1046-55.
    View in: PubMed
    Score: 0.086
  29. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
    View in: PubMed
    Score: 0.081
  30. Uptake of a superparamagnetic contrast agent imaged by MR with high spectral and spatial resolution. Magn Reson Med. 2000 May; 43(5):633-9.
    View in: PubMed
    Score: 0.080
  31. Effect of Echo Times on Prostate Cancer Detection on T2-Weighted Images. Acad Radiol. 2020 11; 27(11):1555-1563.
    View in: PubMed
    Score: 0.078
  32. Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer. Abdom Radiol (NY). 2019 06; 44(6):2233-2243.
    View in: PubMed
    Score: 0.075
  33. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.
    View in: PubMed
    Score: 0.074
  34. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.
    View in: PubMed
    Score: 0.072
  35. Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. AJR Am J Roentgenol. 2019 01; 212(1):124-129.
    View in: PubMed
    Score: 0.072
  36. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.
    View in: PubMed
    Score: 0.071
  37. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.
    View in: PubMed
    Score: 0.070
  38. Performance of T2 Maps in the Detection of Prostate Cancer. Acad Radiol. 2019 01; 26(1):15-21.
    View in: PubMed
    Score: 0.069
  39. Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study. Radiology. 2018 06; 287(3):864-873.
    View in: PubMed
    Score: 0.068
  40. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer. Acad Radiol. 2018 03; 25(3):349-358.
    View in: PubMed
    Score: 0.067
  41. Comparison of region-of-interest-averaged and pixel-averaged analysis of DCE-MRI data based on simulations and pre-clinical experiments. Phys Med Biol. 2017 Sep 05; 62(18):N445-N459.
    View in: PubMed
    Score: 0.066
  42. Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score. AJR Am J Roentgenol. 2016 Sep; 207(3):592-8.
    View in: PubMed
    Score: 0.061
  43. Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation. Radiographics. 2016 Jan-Feb; 36(1):162-75.
    View in: PubMed
    Score: 0.059
  44. Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging. 2015 Oct; 40(7):2523-8.
    View in: PubMed
    Score: 0.058
  45. X-ray fluorescence microscopy demonstrates preferential accumulation of a vanadium-based magnetic resonance imaging contrast agent in murine colonic tumors. Mol Imaging. 2015; 14.
    View in: PubMed
    Score: 0.055
  46. High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol. 2014 Jul; 203(1):85-90.
    View in: PubMed
    Score: 0.053
  47. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.
    View in: PubMed
    Score: 0.053
  48. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.051
  49. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.048
  50. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
    View in: PubMed
    Score: 0.044
  51. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61.
    View in: PubMed
    Score: 0.044
  52. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010 Dec; 257(3):715-23.
    View in: PubMed
    Score: 0.041
  53. The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI data. Phys Med Biol. 2010 Aug 21; 55(16):4871-83.
    View in: PubMed
    Score: 0.041
  54. Characterization of response to radiation mediated gene therapy by means of multimodality imaging. Magn Reson Med. 2009 Aug; 62(2):348-56.
    View in: PubMed
    Score: 0.038
  55. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
    View in: PubMed
    Score: 0.037
  56. High spectral and spatial resolution MRI of age-related changes in murine prostate. Magn Reson Med. 2008 Sep; 60(3):575-81.
    View in: PubMed
    Score: 0.035
  57. Multi-slice DCE-MRI data using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors. MAGMA. 2006 Feb; 19(1):15-21.
    View in: PubMed
    Score: 0.030
  58. A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging. 1998 Sep-Oct; 8(5):1126-34.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.